ORLANDO, Florida — With glucagon peptide-1 receptor agonist (GLP-1 RA) drugs known to have a rapid rebound of weight gain upon discontinuation, women who stop using...
ORLANDO, Florida — With glucagon peptide-1 receptor agonist (GLP-1 RA) drugs known to have a rapid rebound of weight gain upon discontinuation, women who stop using...
ORLANDO, Florida — What to prioritize first in managing early diabetes? That was the question debated on an expert panel at the American Diabetes Association (ADA)...
Researchers have identified a form of B12 deficiency caused by autoantibodies that specifically affects the central nervous system. Discovered while studying a puzzling case of one...
MONTREAL —Tirzepatide (Mounjaro, Eli Lilly), the dual gastric inhibitory polypeptide–glucagon-like peptide 1 (GIP–GLP-1) receptor agonist that has shown significant benefits in diabetes and obesity, may also...
TOPLINE: Bariatric metabolic surgery (BMS) offers a survival advantage over glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in adults with obesity and diabetes for ≤ 10...
TOPLINE: Semaglutide does not appear to increase the risk for postoperative pneumonia in diabetic patients undergoing elective surgery, a new study found. METHODOLOGY: Researchers conducted a...
LISBON — The diabetes and weight-loss drug semaglutide improves heart failure–related symptoms and physical limitations regardless of diuretic use in patients with obesity-related heart failure and...